FOSUN PHARMA (02196): Drug Registration Application for Vincristine Sulfate Injection Accepted by National Medical Products Administration

Stock News

Aug 26

FOSUN PHARMA (02196) announced that its controlling subsidiary Gismer (Wuhan) Pharmaceutical Co., Ltd. has recently received acceptance from the National Medical Products Administration for its drug registration application of Vincristine Sulfate Injection (the "Drug").

The Drug is a chemical pharmaceutical independently developed by the Group (referring to the Company and its controlling subsidiaries/entities). It is intended for the treatment of acute leukemia and can also be used in combination with other anti-tumor drugs for treating Hodgkin's lymphoma, non-Hodgkin's malignant lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.

As of July 2025, the Group's cumulative research and development investment for this Drug amounts to approximately RMB 3.03 million (unaudited). According to the latest data from IQVIA CHPA, the sales of vincristine sulfate injection in mainland China (excluding Hong Kong, Macau, and Taiwan) reached approximately RMB 202 million in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1176183750"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176183750\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176183750?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176183750","market":"nz","top_or_hot":-1,"title":"FOSUN PHARMA (02196): Drug Registration Application for Vincristine Sulfate Injection Accepted by National Medical Products Administration","media":"Stock News","content":"<p>FOSUN PHARMA (02196) announced that its controlling subsidiary Gismer (Wuhan) Pharmaceutical Co., Ltd. has recently received acceptance from the National Medical Products Administration for its drug registration application of Vincristine Sulfate Injection (the \"Drug\").</p>\n<p>The Drug is a chemical pharmaceutical independently developed by the Group (referring to the Company and its controlling subsidiaries/entities). It is intended for the treatment of acute leukemia and can also be used in combination with other anti-tumor drugs for treating Hodgkin's lymphoma, non-Hodgkin's malignant lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.</p>\n<p>As of July 2025, the Group's cumulative research and development investment for this Drug amounts to approximately RMB 3.03 million (unaudited). According to the latest data from IQVIA CHPA, the sales of vincristine sulfate injection in mainland China (excluding Hong Kong, Macau, and Taiwan) reached approximately RMB 202 million in 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA (02196): Drug Registration Application for Vincristine Sulfate Injection Accepted by National Medical Products Administration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA (02196): Drug Registration Application for Vincristine Sulfate Injection Accepted by National Medical Products Administration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-26 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (02196) announced that its controlling subsidiary Gismer (Wuhan) Pharmaceutical Co., Ltd. has recently received acceptance from the National Medical Products Administration for its drug registration application of Vincristine Sulfate Injection (the \"Drug\").</p>\n<p>The Drug is a chemical pharmaceutical independently developed by the Group (referring to the Company and its controlling subsidiaries/entities). It is intended for the treatment of acute leukemia and can also be used in combination with other anti-tumor drugs for treating Hodgkin's lymphoma, non-Hodgkin's malignant lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.</p>\n<p>As of July 2025, the Group's cumulative research and development investment for this Drug amounts to approximately RMB 3.03 million (unaudited). According to the latest data from IQVIA CHPA, the sales of vincristine sulfate injection in mainland China (excluding Hong Kong, Macau, and Taiwan) reached approximately RMB 202 million in 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"","article_id":"1176183750","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176183750","pubTimestamp":1756214074,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (02196) announced that its controlling subsidiary Gismer (Wuhan) Pharmaceutical Co., Ltd. has recently received acceptance from the National Medical Products Administration for its drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0183":"MSCI概念","BK0188":"融资融券","BK1515":"抗疫概念","BK0096":"民营医院","BK1191":"制药","BK0012":"证金概念","BK0175":"白马股","BK0196":"行业龙头","02196":"复星医药","BK0187":"一线龙头","BK0060":"抗癌","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"复星医药(02196)：硫酸长春新碱注射液药品注册申请获国家药品监督管理局受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (02196) announced that its controlling subsidiary Gismer (Wuhan) Pharmaceutical Co., Ltd. has recently received acceptance from the National Medical Products Administration for its drug registration application of Vincristine Sulfate Injection (the \"Drug\").\nThe Drug is a chemical pharmaceutical independently developed by the Group (referring to the Company and its controlling subsidiaries/entities). It is intended for the treatment of acute leukemia and can also be used in combination with other anti-tumor drugs for treating Hodgkin's lymphoma, non-Hodgkin's malignant lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.\nAs of July 2025, the Group's cumulative research and development investment for this Drug amounts to approximately RMB 3.03 million (unaudited). According to the latest data from IQVIA CHPA, the sales of vincristine sulfate injection in mainland China (excluding Hong Kong, Macau, and Taiwan) reached approximately RMB 202 million in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}